ISMELIN Drug Patent Profile
Which patents cover Ismelin, and what generic alternatives are available?
Ismelin is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in ISMELIN is guanethidine monosulfate. There is one drug master file entry for this compound. Additional details are available on the guanethidine monosulfate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ISMELIN?
- What are the global sales for ISMELIN?
- What is Average Wholesale Price for ISMELIN?
Summary for ISMELIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 38 |
| Patent Applications: | 3,853 |
| DailyMed Link: | ISMELIN at DailyMed |
US Patents and Regulatory Information for ISMELIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | ISMELIN | guanethidine monosulfate | TABLET;ORAL | 012329-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Novartis | ISMELIN | guanethidine monosulfate | TABLET;ORAL | 012329-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
